Log in

NASDAQ:ARNA - Arena Pharmaceuticals Stock Price, Forecast & News

$44.54
+1.54 (+3.58 %)
(As of 03/29/2020 01:44 AM ET)
Today's Range
$41.25
Now: $44.54
$45.80
50-Day Range
$34.83
MA: $46.52
$54.15
52-Week Range
$32.95
Now: $44.54
$64.48
Volume949,780 shs
Average Volume790,700 shs
Market Capitalization$2.24 billion
P/E Ratio5.83
Dividend YieldN/A
Beta1.53
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Read More
Arena Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$806.43 million
Cash Flow$8.17 per share
Book Value$21.38 per share

Profitability

Net Income$397.55 million

Miscellaneous

Employees194
Market Cap$2.24 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.


Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

How has Arena Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARNA stock has increased by 10.2% and is now trading at $44.54. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Arena Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arena Pharmaceuticals.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Arena Pharmaceuticals.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released its quarterly earnings results on Wednesday, February, 26th. The biopharmaceutical company reported ($1.76) EPS for the quarter, missing analysts' consensus estimates of ($1.55) by $0.21. The biopharmaceutical company had revenue of $3 million for the quarter, compared to the consensus estimate of $1.06 million. Arena Pharmaceuticals had a return on equity of 34.11% and a net margin of 49.30%. During the same period in the previous year, the company posted $1.35 earnings per share. View Arena Pharmaceuticals' earnings history.

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals shares reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ARNA?

6 brokerages have issued 12-month price objectives for Arena Pharmaceuticals' stock. Their forecasts range from $56.00 to $83.00. On average, they expect Arena Pharmaceuticals' share price to reach $66.00 in the next year. This suggests a possible upside of 48.2% from the stock's current price. View analysts' price targets for Arena Pharmaceuticals.

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Arena Pharmaceuticals is focused on developing its two pipeline candidates — etrasimod and olorinab. The company out-licensed ralinepag to United Therapeutics and the fund is being used to support continuation of clinical development of other candidates. Meanwhile, the company’s decision to sell its manufacturing operations and out-licensing of Belviq to focus on the pipeline is prudent in our view. However, Arena’s pipeline candidates are in mid-stage development, which is a concern as any setback will have a negative impact on Arena’s prospects. Dependence on Belviq royalties is also concerning as the drug’s performance has been lackluster lately in the market, due to competition." (12/30/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight and $62 PT. Arena today reported 1Q financials and provided an update on its clinical programs, including details on the etrasimod Ph3 trial design in ulcerative colitis (UC) that is still expected to initiate mid-year. We think the planned Ph3 UC program is strategically designed to expedite enrollment and support a differentiated commercial profile for etrasimod. We continue to believe IBD represents a large and growing market, and etrasimod is well-positioned in UC with potential to expand into other I&I indications due to its safety profile." (5/8/2019)

Has Arena Pharmaceuticals been receiving favorable news coverage?

News stories about ARNA stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arena Pharmaceuticals earned a news impact score of -2.1 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutArena Pharmaceuticals.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Canopy Growth (CGC), Cytokinetics (CYTK), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), ZIOPHARM Oncology (ZIOP), AT&T (T), Amarin (AMRN), NVIDIA (NVDA) and Novavax (NVAX).

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the following people:
  • Mr. Amit D. Munshi, Pres, CEO & Director (Age 51)
  • Mr. Kevin R. Lind, Exec. VP & CFO (Age 43)
  • Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 51)
  • Dr. Preston S. Klassen, Exec. VP of R&D and Chief Medical Officer (Age 50)

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (3.68%), FMR LLC (2.41%), Alliancebernstein L.P. (2.20%), Partner Fund Management L.P. (2.14%), Norges Bank (1.99%) and Eagle Asset Management Inc. (1.88%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Jayson Donald Alexander Dallas, Kevin Robert Lind, Preston Klassen, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View institutional ownership trends for Arena Pharmaceuticals.

Which institutional investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., State Street Corp, Pictet Asset Management Ltd., Rafferty Asset Management LLC, UBS Group AG, Chartwell Investment Partners LLC, Russell Investments Group Ltd., and First Trust Advisors LP. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Jayson Donald Alexander Dallas, Kevin Robert Lind, Randall E Woods, Robert Lisicki, Steven W Spector, and Vincent Aurentz. View insider buying and selling activity for Arena Pharmaceuticals.

Which institutional investors are buying Arena Pharmaceuticals stock?

ARNA stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Panagora Asset Management Inc., Man Group plc, Point72 Asset Management L.P., Alyeska Investment Group L.P., GW&K Investment Management LLC, Marshall Wace North America L.P., and Rhenman & Partners Asset Management AB. View insider buying and selling activity for Arena Pharmaceuticals.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $44.54.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $2.24 billion and generates $806.43 million in revenue each year. The biopharmaceutical company earns $397.55 million in net income (profit) each year or $7.69 on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe. View additional information about Arena Pharmaceuticals.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is http://www.arenapharm.com/.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]


MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  394 (Vote Outperform)
Underperform Votes:  444 (Vote Underperform)
Total Votes:  838
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel